00:41 , Feb 9, 2019 |  BioCentury  |  Product Development

Genentech takes the wheel

Roche has good cause to call on Genentech to prevent it from losing its long-standing dominance in cancer. While the pharma is late to the party in immuno-oncology, its former biotech unit is behind at...
18:55 , Feb 7, 2019 |  BC Week In Review  |  Clinical News

CHMP recommendations include Ajovy, Vizimpro, Humira biosimilars

EMA's CHMP recommended a basket of approvals and label extensions on Feb. 1, including Ajovy fremanezumab, Vizimpro dacomitinib and two Humira biosimilars. CHMP also backed an expanded label for Forxiga dapagliflozin to include Type I...
00:59 , Feb 7, 2019 |  BioCentury  |  Finance

Chinese Innovation: Threat or Opportunity?

Mounting techno-protectionism in response to China’s innovation drive seems destined to sap U.S. scientific leadership and entrepreneurial vigor, driving talent and capital to Europe and Asia. Biotech offers a compelling alternative to the current trend,...
22:49 , Feb 1, 2019 |  BioCentury  |  Politics, Policy & Law

Trading blows over trade secrets

Roche’s Genentech Inc. unit kept an employee on the payroll in its South San Francisco office for almost a year after it discovered she was stealing trade secrets, watching as she channeled proprietary data to...
21:12 , Feb 1, 2019 |  BC Extra  |  Company News

CHMP recommendations include Ajovy, Vizimpro, Humira biosimilars

EMA's CHMP recommended a basket of approvals and label extensions on Friday, including Ajovy fremanezumab, Vizimpro dacomitinib and two Humira biosimilars. CHMP also backed an expanded label for Forxiga dapagliflozin to include Type I diabetes....
01:09 , Feb 1, 2019 |  BC Week In Review  |  Company News

Report: five companies would take brunt of Trump Part B proposal

The cost of an international reference pricing scheme the Trump administration has proposed for Medicare Part B would fall most heavily on five companies: Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Amgen Inc. (NASDAQ:AMGN), Bristol-Myers Squibb Co. (NYSE:BMY),...
00:04 , Jan 31, 2019 |  BC Extra  |  Politics & Policy

Report: five companies would take brunt of Trump Part B proposal

The cost of an international reference pricing scheme the Trump administration has proposed for Medicare Part B would fall most heavily on five companies: Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Amgen Inc. (NASDAQ:AMGN), Bristol-Myers Squibb Co. (NYSE:BMY),...
00:40 , Jan 25, 2019 |  BC Week In Review  |  Clinical News

Lartruvo fails confirmatory study; Lilly suspending promotion

Eli Lilly and Co. (NYSE:LLY) said on Jan. 18 that it will suspend promotion of Lartruvo olaratumab after it missed the primary endpoints of the Phase III ANNOUNCE trial to treat advanced or metastatic soft...
21:43 , Jan 18, 2019 |  BioCentury  |  Product Development

ImmunoGen’s milestone year

Nearly three years after refocusing the company to boost long-term value creation, ImmunoGen Inc. expects 2019 to be the year the changes will begin to bear fruit, starting with Phase III data from its lead...
13:43 , Jan 18, 2019 |  BC Extra  |  Clinical News

Lartruvo fails confirmatory study; Lilly suspending promotion

Eli Lilly and Co. (NYSE:LLY) said it will suspend promotion of Lartruvo olaratumab after it missed the primary endpoints of the Phase III ANNOUNCE study to treat advanced or metastatic soft tissue sarcoma. The trial...